{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:33:12Z","timestamp":1770899592747,"version":"3.50.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T00:00:00Z","timestamp":1506643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T00:00:00Z","timestamp":1506643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The type 2 vesicular monoamine transporter (VMAT2), by regulating the storage of monoamines transmitters into synaptic vesicles, has a protective role against their cytoplasmic toxicity. Increasing evidence suggests that impairment of VMAT2 neuroprotection contributes to the pathogenesis of Parkinson\u2019s disease (PD). Several transgenic VMAT2 mice models have been developed, however these models lack specificity regarding the monoaminergic system targeting. To circumvent this limitation, we created VMAT2-KO mice specific to the dopamine (DA) nigrostriatal pathway to analyze VMAT2\u2019s involvement in DA depletion-induced motor features associated to PD and examine the relevance of DA toxicity in the pathogenesis of neurodegeneration. Adult VMAT2 floxed mice were injected in the substancia nigra (SN) with an adeno-associated virus (AAV) expressing the Cre-recombinase allowing VMAT2 removal in DA neurons of the nigrostriatal pathway solely. VMAT2 deletion in the SN induced both DA depletion exclusively in the dorsal striatum and motor dysfunction. At 16 weeks post-injection, motor symptoms were accompanied with a decreased in food and water consumption and weight loss. However, despite an accelerating death, degeneration of nigrostriatal neurons was not observed in this model during this time frame. This study highlights a non-cytotoxic role of DA in our genetic model of VMAT2 deletion exclusively in nigrostriatal neurons.<\/jats:p>","DOI":"10.1038\/s41598-017-12810-9","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T11:24:57Z","timestamp":1506338697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Genetic elimination of dopamine vesicular stocks in the nigrostriatal pathway replicates Parkinson\u2019s disease motor symptoms without neuronal degeneration in adult mice"],"prefix":"10.1038","volume":"7","author":[{"given":"Elsa","family":"Isingrini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chlo\u00e9","family":"Guinaudie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9a","family":"C Perret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quentin","family":"Rainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Moquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Gratton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5876-9822","authenticated-orcid":false,"given":"Bruno","family":"Giros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,29]]},"reference":[{"key":"12810_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LM de Lau","year":"2006","unstructured":"de Lau, L. M. & Breteler, M. M. Epidemiology of Parkinson\u2019s disease. The Lancet. Neurology 5, 525\u2013535, https:\/\/doi.org\/10.1016\/S1474-4422(06)70471-9 (2006).","journal-title":"The Lancet. Neurology"},{"key":"12810_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00005072-199603000-00001","volume":"55","author":"LS Forno","year":"1996","unstructured":"Forno, L. S. Neuropathology of Parkinson\u2019s disease. Journal of neuropathology and experimental neurology 55, 259\u2013272 (1996).","journal-title":"Journal of neuropathology and experimental neurology"},{"key":"12810_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic, J. Parkinson\u2019s disease: clinical features and diagnosis. Journal of neurology, neurosurgery, and psychiatry 79, 368\u2013376, https:\/\/doi.org\/10.1136\/jnnp.2007.131045 (2008).","journal-title":"Journal of neurology, neurosurgery, and psychiatry"},{"key":"12810_CR4","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/sj.jcbfm.9600276","volume":"26","author":"NI Bohnen","year":"2006","unstructured":"Bohnen, N. I. et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism 26, 1198\u20131212, https:\/\/doi.org\/10.1038\/sj.jcbfm.9600276 (2006).","journal-title":"Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism"},{"key":"12810_CR5","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1007\/BF01485901","volume":"38","author":"H Ehringer","year":"1960","unstructured":"Ehringer, H. & Hornykiewicz, O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klinische Wochenschrift 38, 1236\u20131239 (1960).","journal-title":"Klinische Wochenschrift"},{"key":"12810_CR6","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1001\/archneur.63.4.584","volume":"63","author":"S Greffard","year":"2006","unstructured":"Greffard, S. et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Archives of neurology 63, 584\u2013588, https:\/\/doi.org\/10.1001\/archneur.63.4.584 (2006).","journal-title":"Archives of neurology"},{"key":"12810_CR7","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1212\/01.wnl.0000191154.78131.f6","volume":"65","author":"R Hilker","year":"2005","unstructured":"Hilker, R. et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65, 1716\u20131722, https:\/\/doi.org\/10.1212\/01.wnl.0000191154.78131.f6 (2005).","journal-title":"Neurology"},{"key":"12810_CR8","doi-asserted-by":"publisher","unstructured":"Jenner, P. Oxidative stress in Parkinson\u2019s disease. Annals of neurology 53 (Suppl 3), S26\u201336; discussion S36\u201328, doi:https:\/\/doi.org\/10.1002\/ana.10483 (2003).","DOI":"10.1002\/ana.10483"},{"issue":"Suppl","key":"12810_CR9","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1002\/ana.410320714","volume":"32","author":"P Jenner","year":"1992","unstructured":"Jenner, P., Dexter, D. T., Sian, J., Schapira, A. H. & Marsden, C. D. Oxidative stress as a cause of nigral cell death in Parkinson\u2019s disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson\u2019s Disease Research Group. Annals of neurology 32(Suppl), S82\u201387 (1992).","journal-title":"Annals of neurology"},{"key":"12810_CR10","doi-asserted-by":"publisher","first-page":"S161","DOI":"10.1212\/WNL.47.6_Suppl_3.161S","volume":"47","author":"P Jenner","year":"1996","unstructured":"Jenner, P. & Olanow, C. W. Oxidative stress and the pathogenesis of Parkinson\u2019s disease. Neurology 47, S161\u2013170 (1996).","journal-title":"Neurology"},{"key":"12810_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.freeradbiomed.2013.01.003","volume":"62","author":"LH Sanders","year":"2013","unstructured":"Sanders, L. H. & Greenamyre, J. T. Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. Free radical biology & medicine 62, 111\u2013120, https:\/\/doi.org\/10.1016\/j.freeradbiomed.2013.01.003 (2013).","journal-title":"Free radical biology & medicine"},{"key":"12810_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1017\/S0317167100046333","volume":"11","author":"JW Langston","year":"1984","unstructured":"Langston, J. W. & Ballard, P. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson\u2019s disease. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 11, 160\u2013165 (1984).","journal-title":"The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques"},{"key":"12810_CR13","volume":"309","author":"JW Langston","year":"1983","unstructured":"Langston, J. W. & Ballard, P. A. Jr. Parkinson\u2019s disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. The New England journal of medicine 309, 310 (1983).","journal-title":"The New England journal of medicine"},{"key":"12810_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0006-8993(86)90905-4","volume":"376","author":"GA Ricaurte","year":"1986","unstructured":"Ricaurte, G. A. et al. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain research 376, 117\u2013124 (1986).","journal-title":"Brain research"},{"key":"12810_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1023\/A:1010991020245","volume":"21","author":"A Barzilai","year":"2001","unstructured":"Barzilai, A., Melamed, E. & Shirvan, A. Is there a rationale for neuroprotection against dopamine toxicity in Parkinson\u2019s disease? Cellular and molecular neurobiology 21, 215\u2013235 (2001).","journal-title":"Cellular and molecular neurobiology"},{"key":"12810_CR16","doi-asserted-by":"publisher","first-page":"6594","DOI":"10.1523\/JNEUROSCI.0970-05.2005","volume":"25","author":"DK Choi","year":"2005","unstructured":"Choi, D. K. et al. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson\u2019s disease in mice. The Journal of neuroscience: the official journal of the Society for Neuroscience 25, 6594\u20136600, https:\/\/doi.org\/10.1523\/JNEUROSCI.0970-05.2005 (2005).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"12810_CR17","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/ana.410260518","volume":"26","author":"G Cohen","year":"1989","unstructured":"Cohen, G. & Spina, M. B. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Annals of neurology 26, 689\u2013690, https:\/\/doi.org\/10.1002\/ana.410260518 (1989).","journal-title":"Annals of neurology"},{"key":"12810_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/0304-3940(94)90258-5","volume":"170","author":"I Ziv","year":"1994","unstructured":"Ziv, I. et al. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons\u2013a possible novel pathogenetic mechanism in Parkinson\u2019s disease. Neuroscience letters 170, 136\u2013140 (1994).","journal-title":"Neuroscience letters"},{"key":"12810_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1385\/1-59259-142-6:73","volume":"62","author":"I Ziv","year":"2001","unstructured":"Ziv, I., Shirvan, A., Offen, D., Barzilai, A. & Melamed, E. Molecular biology of dopamine-induced apoptosis: possible implications for Parkinson\u2019s disease. Methods in molecular medicine 62, 73\u201387, https:\/\/doi.org\/10.1385\/1-59259-142-6:73 (2001).","journal-title":"Methods in molecular medicine"},{"key":"12810_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s12035-009-8059-y","volume":"39","author":"TS Guillot","year":"2009","unstructured":"Guillot, T. S. & Miller, G. W. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Molecular neurobiology 39, 149\u2013170, https:\/\/doi.org\/10.1007\/s12035-009-8059-y (2009).","journal-title":"Molecular neurobiology"},{"key":"12810_CR21","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/0092-8674(92)90425-C","volume":"70","author":"Y Liu","year":"1992","unstructured":"Liu, Y. et al. A cDNA that suppresses MPP+\u2009toxicity encodes a vesicular amine transporter. Cell 70, 539\u2013551 (1992).","journal-title":"Cell"},{"key":"12810_CR22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1242\/jeb.196.1.251","volume":"196","author":"JP Henry","year":"1994","unstructured":"Henry, J. P. et al. Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. The Journal of experimental biology 196, 251\u2013262 (1994).","journal-title":"The Journal of experimental biology"},{"key":"12810_CR23","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1523\/JNEUROSCI.20-19-07297.2000","volume":"20","author":"EN Pothos","year":"2000","unstructured":"Pothos, E. N. et al. Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. The Journal of neuroscience: the official journal of the Society for Neuroscience 20, 7297\u20137306 (2000).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"12810_CR24","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/ana.410430503","volume":"43","author":"GR Uhl","year":"1998","unstructured":"Uhl, G. R. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson\u2019s disease. Annals of neurology 43, 555\u2013560, https:\/\/doi.org\/10.1002\/ana.410430503 (1998).","journal-title":"Annals of neurology"},{"key":"12810_CR25","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/S0896-6273(00)80418-3","volume":"19","author":"EA Fon","year":"1997","unstructured":"Fon, E. A. et al. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19, 1271\u20131283 (1997).","journal-title":"Neuron"},{"key":"12810_CR26","doi-asserted-by":"publisher","first-page":"9938","DOI":"10.1073\/pnas.94.18.9938","volume":"94","author":"N Takahashi","year":"1997","unstructured":"Takahashi, N. et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proceedings of the National Academy of Sciences of the United States of America 94, 9938\u20139943 (1997).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"12810_CR27","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0896-6273(00)80419-5","volume":"19","author":"YM Wang","year":"1997","unstructured":"Wang, Y. M. et al. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19, 1285\u20131296 (1997).","journal-title":"Neuron"},{"key":"12810_CR28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1385\/JMN:27:3:277","volume":"27","author":"S Kariya","year":"2005","unstructured":"Kariya, S., Takahashi, N., Hirano, M. & Ueno, S. Increased vulnerability to L-DOPA toxicity in dopaminergic neurons From VMAT2 heterozygote knockout mice. Journal of molecular neuroscience: MN 27, 277\u2013279, https:\/\/doi.org\/10.1385\/JMN:27:3:277 (2005).","journal-title":"Journal of molecular neuroscience: MN"},{"key":"12810_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/toxsci\/kfw106","volume":"153","author":"KM Lohr","year":"2016","unstructured":"Lohr, K. M. et al. Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals. Toxicological sciences: an official journal of the Society of Toxicology 153, 79\u201388, https:\/\/doi.org\/10.1093\/toxsci\/kfw106 (2016).","journal-title":"Toxicological sciences: an official journal of the Society of Toxicology"},{"key":"12810_CR30","doi-asserted-by":"publisher","first-page":"8138","DOI":"10.1523\/JNEUROSCI.0319-07.2007","volume":"27","author":"WM Caudle","year":"2007","unstructured":"Caudle, W. M. et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. The Journal of neuroscience: the official journal of the Society for Neuroscience 27, 8138\u20138148, https:\/\/doi.org\/10.1523\/JNEUROSCI.0319-07.2007 (2007).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"12810_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/hmg\/ddi445","volume":"15","author":"CE Glatt","year":"2006","unstructured":"Glatt, C. E., Wahner, A. D., White, D. J., Ruiz-Linares, A. & Ritz, B. Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Human molecular genetics 15, 299\u2013305, https:\/\/doi.org\/10.1093\/hmg\/ddi445 (2006).","journal-title":"Human molecular genetics"},{"key":"12810_CR32","doi-asserted-by":"publisher","first-page":"8210","DOI":"10.1523\/JNEUROSCI.5456-13.2014","volume":"34","author":"C Pifl","year":"2014","unstructured":"Pifl, C. et al. Is Parkinson\u2019s disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum. The Journal of neuroscience: the official journal of the Society for Neuroscience 34, 8210\u20138218, https:\/\/doi.org\/10.1523\/JNEUROSCI.5456-13.2014 (2014).","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"12810_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1503\/jpn.150028","volume":"41","author":"E Isingrini","year":"2016","unstructured":"Isingrini, E. et al. Selective genetic disruption of dopaminergic, serotonergic and noradrenergic neurotransmission: insights into motor, emotional and addictive behaviour. Journal of psychiatry & neuroscience: JPN 41, 169\u2013181 (2016).","journal-title":"Journal of psychiatry & neuroscience: JPN"},{"key":"12810_CR34","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nn.4245","volume":"19","author":"E Isingrini","year":"2016","unstructured":"Isingrini, E. et al. Resilience to chronic stress is mediated by noradrenergic regulation of dopamine neurons. Nature neuroscience 19, 560\u2013563, https:\/\/doi.org\/10.1038\/nn.4245 (2016).","journal-title":"Nature neuroscience"},{"key":"12810_CR35","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1038\/npp.2011.142","volume":"36","author":"N Narboux-Neme","year":"2011","unstructured":"Narboux-Neme, N. et al. Severe serotonin depletion after conditional deletion of the vesicular monoamine transporter 2 gene in serotonin neurons: neural and behavioral consequences. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 36, 2538\u20132550, https:\/\/doi.org\/10.1038\/npp.2011.142 (2011).","journal-title":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology"},{"key":"12810_CR36","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/0092-8674(95)90145-0","volume":"83","author":"QY Zhou","year":"1995","unstructured":"Zhou, Q. Y. & Palmiter, R. D. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83, 1197\u20131209 (1995).","journal-title":"Cell"},{"key":"12810_CR37","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0014-2999(76)90042-X","volume":"37","author":"ET Iwamoto","year":"1976","unstructured":"Iwamoto, E. T., Loh, H. H. & Way, E. L. Circling behavior in rats with 6-hydroxydopamine or electrolytic nigral lesions. European journal of pharmacology 37, 339\u2013356 (1976).","journal-title":"European journal of pharmacology"},{"key":"12810_CR38","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1006\/exnr.1998.6848","volume":"152","author":"D Kirik","year":"1998","unstructured":"Kirik, D., Rosenblad, C. & Bjorklund, A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Experimental neurology 152, 259\u2013277, https:\/\/doi.org\/10.1006\/exnr.1998.6848 (1998).","journal-title":"Experimental neurology"},{"key":"12810_CR39","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nature09159","volume":"466","author":"AV Kravitz","year":"2010","unstructured":"Kravitz, A. V. et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 466, 622\u2013626, https:\/\/doi.org\/10.1038\/nature09159 (2010).","journal-title":"Nature"},{"key":"12810_CR40","first-page":"41","volume":"2","author":"K Fuxe","year":"1976","unstructured":"Fuxe, K. & Ungerstedt, U. Antiparkinsonian drugs and dopaminergic neostriatal mechanisms: studies in rats with unilateral 6-hydroxydopamine (=6-OH-DA)-induced degeneration of the nigro-neostriatal DA pathway and quantitative recording of rotational behaviour. Pharmacology & therapeutics. Part B: General & systematic pharmacology 2, 41\u201347 (1976).","journal-title":"Pharmacology & therapeutics. Part B: General & systematic pharmacology"},{"key":"12810_CR41","first-page":"37","volume":"2","author":"U Ungerstedt","year":"1976","unstructured":"Ungerstedt, U. 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome. Pharmacology & therapeutics. Part B: General & systematic pharmacology 2, 37\u201340 (1976).","journal-title":"Pharmacology & therapeutics. Part B: General & systematic pharmacology"},{"key":"12810_CR42","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.tins.2007.03.006","volume":"30","author":"A Bjorklund","year":"2007","unstructured":"Bjorklund, A. & Dunnett, S. B. Dopamine neuron systems in the brain: an update. Trends in neurosciences 30, 194\u2013202, https:\/\/doi.org\/10.1016\/j.tins.2007.03.006 (2007).","journal-title":"Trends in neurosciences"},{"key":"12810_CR43","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/0165-6147(94)90323-9","volume":"15","author":"P Seeman","year":"1994","unstructured":"Seeman, P. & Van Tol, H. H. Dopamine receptor pharmacology. Trends in pharmacological sciences 15, 264\u2013270 (1994).","journal-title":"Trends in pharmacological sciences"},{"key":"12810_CR44","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/374640a0","volume":"374","author":"QY Zhou","year":"1995","unstructured":"Zhou, Q. Y., Quaife, C. J. & Palmiter, R. D. Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature 374, 640\u2013643, https:\/\/doi.org\/10.1038\/374640a0 (1995).","journal-title":"Nature"},{"key":"12810_CR45","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1111\/j.1600-0854.2008.00771.x","volume":"9","author":"H Fei","year":"2008","unstructured":"Fei, H., Grygoruk, A., Brooks, E. S., Chen, A. & Krantz, D. E. Trafficking of vesicular neurotransmitter transporters. Traffic 9, 1425\u20131436, https:\/\/doi.org\/10.1111\/j.1600-0854.2008.00771.x (2008).","journal-title":"Traffic"},{"key":"12810_CR46","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/0959-4388(92)90023-E","volume":"2","author":"RH Edwards","year":"1992","unstructured":"Edwards, R. H. The transport of neurotransmitters into synaptic vesicles. Current opinion in neurobiology 2, 586\u2013594 (1992).","journal-title":"Current opinion in neurobiology"},{"key":"12810_CR47","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.neuron.2007.09.001","volume":"55","author":"RH Edwards","year":"2007","unstructured":"Edwards, R. H. The neurotransmitter cycle and quantal size. Neuron 55, 835\u2013858, https:\/\/doi.org\/10.1016\/j.neuron.2007.09.001 (2007).","journal-title":"Neuron"},{"key":"12810_CR48","doi-asserted-by":"publisher","first-page":"5321","DOI":"10.1128\/MCB.21.16.5321-5331.2001","volume":"21","author":"KA Mooslehner","year":"2001","unstructured":"Mooslehner, K. A. et al. Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism. Molecular and cellular biology 21, 5321\u20135331, https:\/\/doi.org\/10.1128\/MCB.21.16.5321-5331.2001 (2001).","journal-title":"Molecular and cellular biology"},{"issue":"Suppl 1","key":"12810_CR49","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/jnc.13731","volume":"139","author":"A Bose","year":"2016","unstructured":"Bose, A. & Beal, M. F. Mitochondrial dysfunction in Parkinson\u2019s disease. Journal of neurochemistry 139(Suppl 1), 216\u2013231, https:\/\/doi.org\/10.1111\/jnc.13731 (2016).","journal-title":"Journal of neurochemistry"},{"key":"12810_CR50","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1046\/j.1471-4159.1999.0731127.x","volume":"73","author":"SB Berman","year":"1999","unstructured":"Berman, S. B. & Hastings, T. G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson\u2019s disease. Journal of neurochemistry 73, 1127\u20131137 (1999).","journal-title":"Journal of neurochemistry"},{"key":"12810_CR51","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nature05292","volume":"443","author":"MT Lin","year":"2006","unstructured":"Lin, M. T. & Beal, M. F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787\u2013795, https:\/\/doi.org\/10.1038\/nature05292 (2006).","journal-title":"Nature"},{"key":"12810_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2015.00091","volume":"9","author":"J Blesa","year":"2015","unstructured":"Blesa, J., Trigo-Damas, I., Quiroga-Varela, A. & Jackson-Lewis, V. R. Oxidative stress and Parkinson\u2019s disease. Frontiers in neuroanatomy 9, 91, https:\/\/doi.org\/10.3389\/fnana.2015.00091 (2015).","journal-title":"Frontiers in neuroanatomy"},{"key":"12810_CR53","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1006\/exnr.1998.7008","volume":"156","author":"GW Miller","year":"1999","unstructured":"Miller, G. W. et al. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson\u2019s disease. Experimental neurology 156, 138\u2013148, https:\/\/doi.org\/10.1006\/exnr.1998.7008 (1999).","journal-title":"Experimental neurology"},{"key":"12810_CR54","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0006-8993(95)00674-F","volume":"692","author":"F Thibaut","year":"1995","unstructured":"Thibaut, F. et al. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson\u2019s disease: a postmortem study using tritiated tetrabenazine. Brain research 692, 233\u2013243 (1995).","journal-title":"Brain research"},{"key":"12810_CR55","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.parkreldis.2015.07.009","volume":"21","author":"DS Goldstein","year":"2015","unstructured":"Goldstein, D. S. et al. Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration. Parkinsonism & related disorders 21, 1013\u20131022, https:\/\/doi.org\/10.1016\/j.parkreldis.2015.07.009 (2015).","journal-title":"Parkinsonism & related disorders"},{"key":"12810_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.1984.tb14495.x","volume":"430","author":"M Goldstein","year":"1984","unstructured":"Goldstein, M. Regulatory mechanisms of dopamine biosynthesis at the tyrosine hydroxylase step. Annals of the New York Academy of Sciences 430, 1\u20135 (1984).","journal-title":"Annals of the New York Academy of Sciences"},{"key":"12810_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(25)27006-9","volume":"148","author":"M Levitt","year":"1965","unstructured":"Levitt, M., Spector, S., Sjoerdsma, A. & Udenfriend, S. Elucidation of the Rate-Limiting Step in Norepinephrine Biosynthesis in the Perfused Guinea-Pig Heart. The Journal of pharmacology and experimental therapeutics 148, 1\u20138 (1965).","journal-title":"The Journal of pharmacology and experimental therapeutics"},{"key":"12810_CR58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/syn.10049","volume":"44","author":"PE Phillips","year":"2002","unstructured":"Phillips, P. E., Hancock, P. J. & Stamford, J. A. Time window of autoreceptor-mediated inhibition of limbic and striatal dopamine release. Synapse 44, 15\u201322, https:\/\/doi.org\/10.1002\/syn.10049 (2002).","journal-title":"Synapse"},{"key":"12810_CR59","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1749-6632.1990.tb32003.x","volume":"604","author":"ME Wolf","year":"1990","unstructured":"Wolf, M. E. & Roth, R. H. Autoreceptor regulation of dopamine synthesis. Annals of the New York Academy of Sciences 604, 323\u2013343 (1990).","journal-title":"Annals of the New York Academy of Sciences"},{"key":"12810_CR60","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejphar.2004.09.049","volume":"504","author":"JG Truong","year":"2004","unstructured":"Truong, J. G., Newman, A. H., Hanson, G. R. & Fleckenstein, A. E. Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein. European journal of pharmacology 504, 27\u201332, https:\/\/doi.org\/10.1016\/j.ejphar.2004.09.049 (2004).","journal-title":"European journal of pharmacology"},{"key":"12810_CR61","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/ana.410410417","volume":"41","author":"GW Miller","year":"1997","unstructured":"Miller, G. W. et al. Immunochemical analysis of dopamine transporter protein in Parkinson\u2019s disease. Annals of neurology 41, 530\u2013539, https:\/\/doi.org\/10.1002\/ana.410410417 (1997).","journal-title":"Annals of neurology"},{"key":"12810_CR62","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev.neuro.22.1.123","volume":"22","author":"CW Olanow","year":"1999","unstructured":"Olanow, C. W. & Tatton, W. G. Etiology and pathogenesis of Parkinson\u2019s disease. Annual review of neuroscience 22, 123\u2013144, https:\/\/doi.org\/10.1146\/annurev.neuro.22.1.123 (1999).","journal-title":"Annual review of neuroscience"},{"key":"12810_CR63","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00213-015-4118-4","volume":"233","author":"CM de Freitas","year":"2016","unstructured":"de Freitas, C. M. et al. Behavioral and neurochemical effects induced by reserpine in mice. Psychopharmacology 233, 457\u2013467, https:\/\/doi.org\/10.1007\/s00213-015-4118-4 (2016).","journal-title":"Psychopharmacology"},{"key":"12810_CR64","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/379606a0","volume":"379","author":"B Giros","year":"1996","unstructured":"Giros, B., Jaber, M., Jones, S. R., Wightman, R. M. & Caron, M. G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606\u2013612, https:\/\/doi.org\/10.1038\/379606a0 (1996).","journal-title":"Nature"},{"key":"12810_CR65","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1046\/j.1460-9568.1999.00764.x","volume":"11","author":"M Jaber","year":"1999","unstructured":"Jaber, M. et al. Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. The European journal of neuroscience 11, 3499\u20133511 (1999).","journal-title":"The European journal of neuroscience"},{"key":"12810_CR66","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1212\/01.WNL.0000126440.16612.51","volume":"62","author":"BE Assmann","year":"2004","unstructured":"Assmann, B. E. et al. Infantile Parkinsonism-dystonia and elevated dopamine metabolites in CSF. Neurology 62, 1872\u20131874 (2004).","journal-title":"Neurology"},{"key":"12810_CR67","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1172\/JCI39060","volume":"119","author":"MA Kurian","year":"2009","unstructured":"Kurian, M. A. et al. Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. The Journal of clinical investigation 119, 1595\u20131603, https:\/\/doi.org\/10.1172\/JCI39060 (2009).","journal-title":"The Journal of clinical investigation"},{"key":"12810_CR68","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S1474-4422(10)70269-6","volume":"10","author":"MA Kurian","year":"2011","unstructured":"Kurian, M. A. et al. Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. The Lancet. Neurology 10, 54\u201362, https:\/\/doi.org\/10.1016\/S1474-4422(10)70269-6 (2011).","journal-title":"The Lancet. Neurology"},{"key":"12810_CR69","doi-asserted-by":"publisher","first-page":"11035","DOI":"10.1073\/pnas.1831768100","volume":"100","author":"M Cyr","year":"2003","unstructured":"Cyr, M. et al. Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proceedings of the National Academy of Sciences of the United States of America 100, 11035\u201311040, https:\/\/doi.org\/10.1073\/pnas.1831768100 (2003).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"12810_CR70","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1460-9568.2004.03465.x","volume":"20","author":"E Morice","year":"2004","unstructured":"Morice, E., Denis, C., Giros, B. & Nosten-Bertrand, M. Phenotypic expression of the targeted null-mutation in the dopamine transporter gene varies as a function of the genetic background. The European journal of neuroscience 20, 120\u2013126, https:\/\/doi.org\/10.1111\/j.1460-9568.2004.03465.x (2004).","journal-title":"The European journal of neuroscience"},{"key":"12810_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2014.00155","volume":"8","author":"J Blesa","year":"2014","unstructured":"Blesa, J. & Przedborski, S. Parkinson\u2019s disease: animal models and dopaminergic cell vulnerability. Frontiers in neuroanatomy 8, 155, https:\/\/doi.org\/10.3389\/fnana.2014.00155 (2014).","journal-title":"Frontiers in neuroanatomy"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12810-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12810-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12810-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T21:57:05Z","timestamp":1750888625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12810-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,29]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["12810"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-12810-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,29]]},"assertion":[{"value":"7 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12432"}}